Reversibility of Fenofibrate Therapy–Induced Renal Function Impairment in ACCORD Type 2 Diabetic Participants
Open accessThe DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: To assess the reversibility of the elevation of serum creatinine levels in patients with diabetes after 5 years of continuous on-trial fenofibrate therapy. RESEARCH DESIGN AND METHODS: An on-drug/off-drug ancillary study to the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Lipid Trial to investigate posttrial changes in serum creatinine and cystatin C. Eligible participants were recruited into a prospective, nested, three-group study based on retrospective on-trial serum creatinine levels: fenofibrate case subjects (n = 321, ≥20% increase after 3 months of therapy); fenofibrate control subjects (n = 175, ≤2% increase); and placebo control subjects (n = 565). Serum creatinine and cystatin C were measured at trial end and 6–8 weeks after discontinuation of trial therapy. RESULTS: At trial end, case subjects had the highest adjusted serum creatinine (± SE) mg/dL (1.11 ± 0.02) and the lowest adjusted estimated glomerular filtration rate (eGFR) (± SE) mL/min/1.73 m2 (68.4 ± 1.0) versus control subjects (1.01 ± 0.02; 74.8 ± 1.3) and placebo subjects (0.98 ± 0.01; 77.8 ± 0.7). After 51 days off-drug, serum creatinine in case subjects was still higher (0.97 ± 0.02) and eGFR still lower (77.8 ± 1.0) than control subjects (0.90 ± 0.02; 81.8 ± 1.3) but not different from placebo subjects (0.99 ± 0.01; 76.6 ± 0.7). Changes in serum cystatin C recapitulated the serum creatinine changes. CONCLUSIONS: Participants with significant initial on-trial increases in serum creatinine (≥20%) returned to the same level of renal function as participants receiving placebo while participants who had ≤2% increase in serum creatinine had net preservation of renal function compared with the same unselected placebo reference group. The fenofibrate-associated on-trial increases in serum creatinine were reversible, and the reversal was complete after 51 days off-drug. The similarity of the cystatin C results suggests that the mechanism of this change is not specific for serum creatinine.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This is a known effect of PPAR-α agonists.[27][28][29]”
From A Placebo-Controlled Trial of Bezafibrate in Primary Biliary Cholangitis (2018) · cites this paper as [29]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“These potential explanations have supported the view that the drug-induced elevations in serum creatinine does not reflect a true deterioration of renal function”
From Effects of Fibrates in Kidney Disease (2012) · cites this paper as [50]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In addition, we confirm prior reports that demonstrated the association of fenofibrate use with preservation of kidney function in patients with diabetes.12, 13”
From Associations of Fenofibrate Therapy With Incidence and Progression of CKD in Patients With Type 2 Diabetes (2019) · cites this paper as [13]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Similarly, reversibility in acute increases in creatinine has been described amongst participants in the ACCORD study (50).”
From Effects of Fibrates in Kidney Disease (2012) · cites this paper as [50]
The cited source says what the claim attributes to it.
In the citing paper
“We used the month 4 eGFR for our baseline eGFR given the increase in creatinine seen with fibrates after initiating therapy.13”
From Associations of Fenofibrate Therapy With Incidence and Progression of CKD in Patients With Type 2 Diabetes (2019) · cites this paper as [13]
4 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Toprak, O., Kurt, H., Sarı, Y., Şarkış, C., Us, H., & Kırık, A. (2017) · Kidney and Blood Pressure Research · doi:10.1159/000468530 · Cited by 29,627
A New Equation to Estimate Glomerular Filtration Rate
Levey, A. S., Stevens, L. A., Schmid, C. H., Zhang, Y. (., Castro, A. F., Feldman, H. I., Kusek, J. W., Eggers, P., Van Lente, F., Greene, T., et al. (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-150-9-200905050-00006 · Cited by 25,603
Levey, A. S., Bosch, J. P., Lewis, J. B., Greene, T., Rogers, N., Roth, D., & for the Modification of Diet in Renal Disease Study Group* (1999) · Annals of Internal Medicine · doi:10.7326/0003-4819-130-6-199903160-00002 · Cited by 15,079
Effects of Combination Lipid Therapy in Type 2 Diabetes Mellitus
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001282 · Cited by 2,837
Stevens, L. A., Coresh, J., Schmid, C. H., Feldman, H. I., Froissart, M., Kusek, J., Rossert, J., Van Lente, F., Bruce, R. D., Zhang, Y. (., et al. (2008) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2007.11.018 · Cited by 1,037
Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial: Design and Methods
Buse, J. B. (2007) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2007.03.003 · Cited by 661
Self-citationon behalf of the FIELD Study investigators, Davis, T. M. E., Ting, R., Best, J. D., Donoghoe, M. W., Drury, P. L., Sullivan, D. R., Jenkins, A. J., O’Connell, R. L., Whiting, M. J., et al. (2011) · Diabetologia · doi:10.1007/s00125-010-1951-1 · Cited by 371
Ansquer, J.-C., Foucher, C., Rattier, S., Taskinen, M.-R., & Steiner, G. (2005) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2004.11.004 · Cited by 264
Fenofibrate Increases Creatininemia by Increasing Metabolic Production of Creatinine
Hottelart, C., El Esper, N., Rose, F., Achard, J.-M., & Fournier, A. (2002) · Nephron · doi:10.1159/000064083 · Cited by 186
Cited by
Items 101–148 of 148
The use of fenofibrate in diabetic retinopathy: Narrative review
Dissanayake, H. A., Kiire, C. A., Preiss, D., & Tan, G. D. (2025) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2025.109135 · Cited by 9
Fenofibrate and renal disease: clinical effects in diabetes
Ting, R.-D., & KEECH, A. C. (2013) · Clinical Lipidology · doi:10.2217/clp.13.69 · Cited by 6
Design, recruitment and baseline characteristics of the LENS trial
The LENS Collaborative Group (2024) · Diabetic Medicine · doi:10.1111/dme.15310 · Cited by 5
Management of Diabetes Mellitus
Jenkins, A. J., SCOTT, E. S., Fulcher, J., Kilov, G., & Januszewski, A. S. (2018) · Contemporary cardiology · doi:10.1007/978-3-319-97622-8_7 · Cited by 6
Role of Dyslipidemia in Patients With Chronic Kidney Disease
Marino, A., & Tannock, L. R. (2013) · Postgraduate Medicine · doi:10.3810/pgm.2013.07.2676 · Cited by 6
Fenofibrate-Induced Osmotic Nephropathy: A Novel Mechanism of Acute Kidney Injury
Lin, R., Viswanathan, S., & Wong, N. (2025) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2025.03.019 · Cited by 5
Investigational drugs in development for hypertriglyceridemia: a coming-of-age story
Rhainds, D., Brodeur, M. R., & Tardif, J. (2019) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2019.1696772 · Cited by 4
Guías de práctica clínica de manejo de la dislipemia en diabéticos y otros grupos de riesgo
Fanlo‐Maresma, M., & Pintó, X. (2015) · Revista Española de Cardiología Suplementos · doi:10.1016/s1131-3587(15)70118-4 · Cited by 10
Królewski, A. S., Haukka, J. K., Dom, Z. I. M., Curovic, V. R., Wu, C., Morieri, M. L., Ihara, K., Tye, S. C., Kobayashi, H. H., Keum, Y., et al. (2025) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.0000000863 · Cited by 7
Atherogenic Dyslipemia Working Group of the Spanish Society of Atherosclerosis and the European Expert Group (2017) · Clínica e Investigación en Arteriosclerosis (English Edition) · doi:10.1016/j.artere.2017.07.002 · Cited by 4
Zimner‐Rapuch, S., Amet, S., Janus, N., Deray, G., & Launay‐Vacher, V. (2014) · Annales de Cardiologie et d Angéiologie · doi:10.1016/j.ancard.2014.04.006 · Cited by 3
Lipid-lowering agents in chronic kidney disease: do fibrates have a role?
Huang, Y., & Hu, Y. (2013) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2013.15-c1 · Cited by 3
Dyslipidemia aterogenna w codziennej praktyce — interdyscyplinarny konsensus polskich ekspertów
Szymański, F. M., Filipiak, K. J., Wożakowska−Kapłon, B., Szaflik, J. P., Dzida, G. J., Kurkowska‐Jastrzębska, I., Narkiewicz, K., Łazicka-Gałecka, M., Gil, R. J., & Gumprecht, J. (2017) · Folia Cardiologica · doi:10.5603/fc.a2016.0106 · Cited by 4
Jerums, G., Ekinci, E. I., Premaratne, E., Baker, S. T., Panagiotopoulos, S., & MacIsaac, R. J. (2015) · Wiley eBooks · doi:10.1002/9781118387658.ch62 · Cited by 3
Jones, P. H., & Brinton, E. A. (2015) · Elsevier eBooks · doi:10.1016/b978-0-323-28786-9.00025-6
Wang, L., Jin, X., & Li, Y. (2025) · Clinical Therapeutics · doi:10.1016/j.clinthera.2025.09.010 · Cited by 1
O’Brien, R. C., Abdallah, K., Dong, X., Hassanein, M. M., Ji, Q., Keşkek, Ş. Ö., López-Jaramillo, P. A., Mehta, R., Raef, H., & Tan, K. (2026) · Journal of Diabetes · doi:10.1111/1753-0407.70193 · Cited by 3
Preiss, D., Logue, J., Sammons, E., Zayed, M., Scotland, G., Tsehaye, M., Emberson, J., Wade, R. L., Wallendszus, K., Stevens, W., et al. (2025) · Health Technology Assessment · doi:10.3310/aaph5610 · Cited by 1
Potential of Fenofibric Acid as Topical Eye Drops for Management of Dry Eye Syndrome
Tan, G., Chen, M., Xie, P., Bian, C., Wang, W., Wu, S., Jin, Y., & Cheng, L. (2026) · Pharmaceutics · doi:10.3390/pharmaceutics18080998 · Cited by 1
Parte III. Control clínico del tratamiento con fenofibrato
(2016) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/s0214-9168(16)30085-7 · Cited by 1
Características de la enfermedad renal diabética
Valero, J. A. (2023) · Diabetes práctica · doi:10.52102/diabet/pract.renal.art4 · Cited by 1
Insuficiencia renal asociada al uso de fibratos (n = 46)
Casas, C. R. C., Díaz, B. M., Tabarés, L. G., Gomez‐Larrambe, N., González, L. C., Merino, M. L. G., & Varela, J. C. (2016) · Nefrología · doi:10.1016/j.nefro.2016.09.013 · Cited by 1
Precision Medicine Approaches for Management of Type 2 Diabetes
Chen, D., Fulcher, J., SCOTT, E. S., & Jenkins, A. J. (2022) · Springer eBooks · doi:10.1007/978-3-030-98927-9_1 · Cited by 3
The role of fibrates in chronic kidney disease and diabetes mellitus
Kahn, M. R., Robbins, M. J., Kim, M. C., & Fuster, V. (2013) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2013.15-c2 · Cited by 1
How Lipid-Lowering Agents Work: The Good, the Bad, and the Ugly
Turgut, F. H., Üstün, İ., & Gökçe, C. (2014) · Springer eBooks · doi:10.1007/978-1-4939-0515-7_4
Fenofibrate-Associated Creatinine Increase: A Case for More Prospective Studies
Ncube, V., Starkey, B. J., & Wang, T. (2012) · World Journal of Nephrology and Urology
Fibrates: Risk Benefits and Role in Treating Dyslipidemias
Jun, M., & Perkovic, V. (2015) · Contemporary Endocrinology · doi:10.1007/978-1-60761-424-1_25
Renal failure related to fibrates administration ( n = 46)
Casas, C. R. C., Díaz, B. M., Tabarés, L. G., Gomez‐Larrambe, N., González, L. C., Merino, M. L. G., & Varela, J. C. (2017) · Nefrología (English Edition) · doi:10.1016/j.nefroe.2017.04.006
Increased Survival after Treatment of Canine Hemangiosarcoma with Fenofibrate
Ecke, J., Valle, L., Struckhoff, A. P., Waligórski, P., & Reiss, K. (2015) · International Journal of Veterinary Science and Research · doi:10.17352/ijvsr.000003
Drugs for Treatment of Dyslipidemia Available in the USA
Streja, E., & Streja, D. A. (2019) · Springer eBooks · doi:10.1007/978-3-319-97765-2_13
Abo-Ouf, A. M., & Arafa, M. A. A. (2018) · Al-Azhar Medical Journal · doi:10.21608/0053059
Fenofibrate-Associated Creatinine Increase: A Case for More Prospective Studies
Ncube (2012) · World Journal of Nephrology and Urology · doi:10.4021/wjnu55w
Parte II. Combinación de estatina más fibrato (libre y fija)
(2016) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/s0214-9168(16)30084-5
Ginsberg, H. N. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-88286-6.00031-5
Self-citationBrinton, E. A., & Pulipati, V. P. (2023) · Contemporary diabetes · doi:10.1007/978-3-031-26681-2_24
Kazé, A. D., Ndumele, C. E., Jaar, B. G., Santhanam, P., Yeneneh, B. T., Mookadam, F., Tung, R. H., Fonarow, G. C., Crews, D. C., & Echouffo-Tcheugui, J. B. (2025) · JACC Advances · doi:10.1016/j.jacadv.2025.101903 · Cited by 1
Williams, P. H., Huang, J., Rasmont, P., & An, J. (2016) · INFM-OAR (INFN Catania) · doi:10.5281/zenodo.192318
Bueno Junior, C. R., Bano, A., TANG, Y., SUN, X., Abate, A., Hall, E., Mitri, J., Morieri, M. L., Shah, H., & Doria, A. (2023) · Figshare · doi:10.6084/m9.figshare.23583664
Kazé, A. D., Jaar, B. G., Fonarow, G. C., & Echouffo-Tcheugui, J. B. (2022) · Figshare · doi:10.6084/m9.figshare.19445915
Song, J., Dou, C.-Y., Chen, X., Hu, J. K., Xu, F., Li, L.-C., Li, J., Jiang, Q., & Zheng, W. (2026) · medRxiv · doi:10.64898/2026.01.01.26343323
Chitsazi, M. R., Safari, F., Malekpour, E., Mirzaei, S. A., Shafieyoun, M. H., Golafshan, F., Rouzbahani, H., Nekookhoo, M., Noursina, A., & Siavash, M. (2026) · Journal of Research in Medical Sciences · doi:10.4103/jrms.jrms_441_25
Song, J., Dou, C.-Y., Chen, X., Hu, J. K., Xu, F., Li, L.-C., Li, J., Jiang, Q., & Zheng, W. (2026) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-026-05302-z
Luo, J., Dai, Y., Wu, C., Lan, C., Shi, J., Qi, J., Hua, S., An, Y., Wang, L., Li, P., et al. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1842847
Olshvang, D., Harris, C., Chellappa, R. R., Parikh, C., & Santhanam, P. (2026) · medRxiv · doi:10.64898/2026.08.04.26359704
Bhandari, M., Devkota, S., Dhital, R., Subedi, S., & Adhikari, S. (2026) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2026.113543
Non-statin Therapies for CKD with Dyslipidemia
Mucsi, I. (2014) · Springer eBooks · doi:10.1007/978-1-4939-0515-7_9
Metadata
- Authors
- Mychaleckyj, J. C., Craven, T., Nayak, U., Buse, J., Crouse, J. R., Elam, M., Kirchner, K., Lorber, D., Marcovina, S., Sivitz, W., Sperl-Hillen, J., Bonds, D. E., & Ginsberg, H. N.
- Affiliations
- University of Virginia (US)
- Wake Forest University Health Sciences (US)
- University of North Carolina at Chapel Hill (US)
- Memphis VA Medical Center (US)
- G.V. (Sonny) Montgomery VA Medical Center (US)
- New York Hospital Queens (US)
- University of Washington (US)
- University of Iowa (US)
- Health Partners Research Foundation, Minneapolis, Minnesota
- National Institutes of Health (US)
- Columbia University (US)
- Corresponding author
- Mychaleckyj, Josyf C.
- ORCID
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2012-04-11
- Volume
- 35
- Issue
- 5
- Pages
- 1008-1014
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC3329840
- OpenAlex
- W2022162088
- Cited by
- 149
- References
- 20
- Citations by year
- 2026: 10 · 2025: 10 · 2024: 8 · 2023: 12 · 2022: 9 · 2021: 8 · 2020: 9 · 2019: 7 · 2018: 10 · 2017: 13 · 2016: 13 · 2015: 12 · 2014: 13 · 2013: 11 · 2012: 3
- FWCI
- 9.85
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Diabetes Care (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Carolina Digital Repository (University of North Carolina at Chapel Hill) (submittedVersion)
- Hispana (submittedVersion)
- UNC Libraries
- Funders
- American Diabetes Association
- Abbott Laboratories
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- GlaxoSmithKline
- Sanofi
- Osiris Therapeutics
- MannKind Corporation
- Halozyme
- Omron Healthcare
- Bayer HealthCare
- Novo Nordisk
- National Institutes of Health (n01hc95183-23-0-0, n01hc95180-24-0-1, n01hc95184-24-0-1, n01hc95181-23-0-1, n01hc95182-23-0-1, n01hc95178-28-0-1, n01hc95179-25-0-0)
- Centers for Disease Control and Prevention
- National Institute on Aging
- National Heart, Lung, and Blood Institute (N01- HC-95181, N01 HC095184, N01-HC- 95180, N01-HC-95178, N01 HC095182, N01 HC095181, Y01 HC001010, N01-HC-095183, N01 HC095178, N01-HC-95184, N01HC95179, IAAY1-HC-1010, IAA #Y1-HC-9035, N01 HC095180, Y01 HC009035, N01‐HC‐95183, N01-HC-95182, N01 HC095179)
- National Eye Institute
- National Institute of Diabetes and Digestive and Kidney Diseases
- Topics
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Health Sciences › Medicine › Nephrology › Acute Kidney Injury Research
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Keywords
- fenofibrate, serum creatinine, cystatin C, estimated glomerular filtration rate, type 2 diabetes, drug discontinuation, renal function recovery, lipid-lowering therapy, placebo comparison, cardiovascular risk in diabetes
- MeSH terms
- Aged, Hypolipidemic Agents, Creatinine, Glomerular Filtration Rate, Humans, Middle Aged, Fenofibrate, Renal Insufficiency
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.